| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 480.1 | 394.2 |
| Profit before tax | 14.7 | 100.7 |
| Net income | 16.3 | 82.8 |
| EPS (diluted, $ a share) | $0.09 | $0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -80.3% |
|---|---|
| Revenue, year on year | +21.8% |
| Operating margin | 7.5% |
10-Q filed with the SEC, NASDAQ: ALKS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alkermes plc.: key numbers
- Share price
- $46.53Close, Nov 16
- Market cap
- $7.82B
- Shares outstanding
- 168.04MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alkermes plc.
All →Alkermes Court & Legal Update
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
- Counterparty
- Teva Pharmaceuticals, Inc.
Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $94K of Stock
David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,035 shares of Alkermes plc. at $46.17 a share, worth $94K in total on Nov 3, 2026. Shares held after the trade: 219,353 (-0.9%).
- Value
- $94K
- Shares
- 2,035
- Price
- $46.17
- Role
- EVP, CLO, Alkermes, Inc.
- Holding change
- -0.9%
- Trade date
- Nov 3, 2026
Alkermes Financial Results
Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.
- Term
- 3 months
“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”
Blair Jackson, President and Chief Executive Officer
Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $83.5K of Stock
David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,034 shares of Alkermes plc. at $41.03 a share, worth $83.5K in total on Oct 2, 2026. Shares held after the trade: 221,388 (-0.9%).
- Value
- $83.5K
- Shares
- 2,034
- Price
- $41.03
- Role
- EVP, CLO, Alkermes, Inc.
- Holding change
- -0.9%
- Trade date
- Oct 2, 2026
Alkermes Clinical Trial Data
Alkermes announced positive topline results from a Phase 1b proof-of-concept study for ALKS 7290, a novel orexin 2 receptor agonist for the treatment of ADHD. The study demonstrated clinically meaningful improvements in ADHD symptoms as measured by the AISRS and CGI-S scales, marking the first clinical evidence of an orexin agonist's efficacy in ADHD. A Phase 2 study is currently enrolling with data expected in 2027.
Alkermes Leadership Change
Alkermes plc has appointed Anne C. Whitaker to its Board of Directors, effective September 14, 2026, increasing the board size to 11 members. Ms. Whitaker, a seasoned biopharmaceutical executive, will receive an initial new director equity award with a target value of $600,000. Her appointment is intended to support the company's strategic focus on its neuroscience pipeline and commercial growth.
- Counterparty
- Anne C. Whitaker